Abstract
Aims Despite a higher prevalence of overweight/obesity in black South African women compared to men, the prevalence of type 2 diabetes does not differ. We explored if this could be due to sex differences in insulin sensitivity, clearance and/or beta-cell function, and also sex-specific associations with total and regional adiposity.
Methods This cross-sectional study included 804 black South African men (n=388) and women (n=416). Dual-energy x-ray absorptiometry was used to measure total and regional adiposity. Insulin sensitivity (Matsuda index), secretion (C-peptide index) and clearance (C-peptide/insulin ratio) were estimated from an oral glucose tolerance test.
Results After adjusting for sex differences in fat mass index, men were less insulin sensitive and had lower beta cell function than women (p<0.001), with the strength of the associations with measures of total and central adiposity being greater in men than women (p<0.001 for interactions). Further, the association between total adiposity and type 2 diabetes risk was also greater in men than women (relative risk ratio (95% confidence interval): 2.05 (1.42– 2.96), p<0.001 vs. 1.38 (1.03–1.85), p=0.031).
Conclusion With increasing adiposity, particularly increased centralisation of body fat linked to decreased insulin sensitivity and beta cell function, black African men are at greater risk for type 2 diabetes than their female counterparts.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was jointly funded by the South African Medical Research Council (MRC) from South African National Department of Health, MRC UK (via the Newton Fund) and GSK Africa Non-Communicable Disease Open Lab (via a supporting Grant project Number: ES/N013891/1) and South African National Research Foundation (Grant no: UID:98561).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Human Research Ethics Committee (HREC) of the University of the Witwatersrand (M160604 and M160975), Johannesburg, South Africa.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email addresses:
CNK: klekufe{at}gmail.com
LKM: lisa.micklesfield{at}wits.ac.za
MM: maphokomasemola{at}gmail.com
TC: tinashedoc{at}gmail.com
APK: andre.kengne{at}mrc.ac.za
FK: fredrik.karpe{at}ocdem.ox.ac.uk
SAN: shane.norris{at}wits.ac.za
NC: nigel.crowther{at}nhls.ac.za
TO: tommy.g.olsson{at}umu.se
JHG: julia.goedecke{at}mrc.ac.za
Data Availability
All data produced in the present study are available upon reasonable request to the authors
